COMMUNIQUÉS West-GlobeNewswire

Pheton Holdings Ltd Announces Closing of Initial Public Offering

06/09/2024 - 22:08

BEIJING, China, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products [...]

Elutia Celebrates First Year

06/09/2024 - 22:23

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting [...]

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

06/09/2024 - 22:30

CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058 shares of common [...]

Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

06/09/2024 - 22:30

PURCHASE, NY, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued an inducement award to a new employee. Effective [...]

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06/09/2024 - 22:30

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06/09/2024 - 22:32

NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]

Better Choice Company Provides Shareholder Update on Balance Sheet

05/09/2024 - 14:30

Pro Forma Adjusted Net Tangible Book Value Per Share (NTBVPS) Increases 6% to $4.07 per share Pro Forma Adjusted Net Current Asset Value Per Share (NCAVPS) Increases 16% to $3.94 per share TAMPA, Fla., Sept. 05, 2024 ( [...]

Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission

05/09/2024 - 14:30

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]

Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting

05/09/2024 - 14:30

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, [...]

Lifeward’s First Annual Step Challenge Donates €5,000 to German Association for People Living with Spinal Cord Injury

05/09/2024 - 14:30

As part of the fundraising “Step Challenge”, ReWalk users in Germany completed 424,844 steps to raise 5,000 Euros for the European Spinal Cord Injury Federation (“ESCIF”) MARLBOROUGH, Mass., BERLIN, Germany, and YOKNEAM [...]

TerrAscend to Participate in the ATB Capital Markets 2024 Life Sciences Institutional Investor Conference on September 18th in NYC

05/09/2024 - 14:30

TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that its executive management team will [...]

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 14:45

LA JOLLA, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the [...]

Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

05/09/2024 - 15:00

PALO ALTO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]

Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024

05/09/2024 - 15:00

AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data [...]

Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors

05/09/2024 - 15:00

TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain [...]

Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

05/09/2024 - 15:00

GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation [...]

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

05/09/2024 - 15:00

Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions HOUSTON, TX, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( [...]

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

05/09/2024 - 15:00

CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per [...]

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

05/09/2024 - 15:00

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review [...]